You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
The new company hopes to turn recombinant adeno-associated virus-based gene editing, which has minimal off-target effects, into new therapies.
NEW YORK (GenomeWeb News) – Pacific Biosciences has filed a prospectus for the resale of up to 5.5 million shares of its stock, issuable upon the exercise of warrants.
NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday that its fourth-quarter revenues fell 52 percent year over year but were up sequentially as product revenue jumped from the third quarter.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.